Press Release

Cord Blood America Key Executives Featured on ABC's Good Morning America

Los Angeles, CA (March 22, 2007) – Cord Blood America, Inc. (OTC BB: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that Jack Goldberg, MD, Medical Director of the Company's subsidiary CorCell was featured today on ABC Network's "Good Morning America" in a feature on public and private umbilical cord blood banking.

"Good Morning America approached us after the announcement that cord blood collected and stored by CorCell for one of its private, family customers was used in the first autologous cord blood transplant for childhood leukemia anywhere in the world," said Matthew Schissler, Cord Blood America CEO. "While the family involved in that successful procedure requested privacy, Good Morning America pursued another sector of the umbilical cord blood banking story."

"It is very important that the nation's major media (Good Morning America is viewed by more than 5.4 million people daily) are recognizing the importance of banking this potentially life-saving resource," Mr. Schissler said. "The more this story is told, the better it is for families, the industry and its investors."

About Cord Blood America
Cord Blood America (OTC BB:CBAI.OB -News) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. For investor information on Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit www.cordblood-america.com.

Forward-Looking Statements
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement. 

Read more Press Releases by following this link: CorCell Cord Blood Bank News.